Daily, Structured Activity Program Effective for Alzheimer's Patients
Posted on: Wednesday, 17 August 2005, 18:00 CDT
WESTON, Mass., Aug. 17 /PRNewswire/ -- According to an article in the Summer 2005 issue of Activities Directors' Quarterly, individuals in the beginning to middle stages of Alzheimer's disease greatly benefit from a daily, structured activity program.
The Smiles Club, a program for Sisters of St. Joseph, was designed to create a structured environment of enjoyment and activity for Alzheimer's patients. Participants meet daily for five-and-a-half hours of dynamic programming that utilizes the interests of staff members. Daily activities include memory box, painting, crossword puzzles, and singing.
After one year in the program, seventy percent of participants either improved or remained stable. A daily, structured activity program of activities is one of the most powerful, effective interventions for Alzheimer's disease. Participation in such programs slows functional decline and improves patients' quality of life.
These findings underscore the need for more research in this area.
Activity Directors' Quarterly, 470 Boston Post Road, Weston, MA 02493, 781-899-2702, http://www.activitiesdirectors.com/ .
Phone: 781-899-2702 x 142 Fax: 781-899-4900 E-mail: adq@pnpco.com Contact: Richard A. DeVito Sr.
Patients
Activities Directors' Quarterly for Alzheimer's and Other Dementia
CONTACT: Richard A. DeVito Sr. of Activities Directors' Quarterly forAlzheimer's and Other Dementia Patients, +1-781-899-2702 ext. 142,adq@pnpco.com
Source: PRNewswire
Related Articles
- Kendle Appoints John Needham Executive Director and Global Head, Patient Enrollment Strategy
- Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients.
- The Lancet Neurology Publishes Clinical Results of PBT2 in Alzheimer's Disease Patients
- Medivation's Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimer's Disease Patients Over One Year
- Medivation's Dimebon(TM) Significantly Improved Daily Function in Alzheimer's Disease Patients, Resulting in Reduced Need for Caregiver Assistance
- Neuro-Hitech Reports Cognitive Improvement From Phase Two Clinical Trial of Huperzine A In Alzheimer's Disease Patients
- PBT2 Phase IIa Clinical Trial in Alzheimer's Disease Patients
- Constella Group Appoints Dr. Ron Manderscheid As Director of Mental Health and Substance Use Programs
- Predix Pharmaceuticals Announces Positive Findings From First Clinical Trial in Alzheimer's Disease Patients
- Project Director's Perspective*: The Critical Care Family Assistance Program
 |
 |
User Comments (0)
RSS Feeds